BTK and cancer: Indeed, ibrutinib treatment significantly decreases metastatic dissemination of tail vein-injected breast cancer cells to the bone (Conklin et al., 2019); however, it is not known whether decreased osteotropism caused by BTK inhibition is a cancer cell autonomous effect.